Showing 1 - 9 results of 9 for search 'David P Nichols', query time: 0.07s Refine Results
  1. 1
    Therapeutic Effects of α1-Antitrypsin on Psedumonas aeruginosa Infection in ENaC Transgenic Mice.

    Therapeutic Effects of α1-Antitrypsin on Psedumonas aeruginosa Infection in ENaC Transgenic Mice. by David P Nichols, Di Jiang, Carrie Happoldt, Reena Berman, Hong Wei Chu

    Published 2015-01-01
    Get full text
    Article
  2. 2
    SERCA2 regulates non-CF and CF airway epithelial cell response to ozone.

    SERCA2 regulates non-CF and CF airway epithelial cell response to ozone. by Shama Ahmad, David P Nichols, Matthew Strand, Raymond C Rancourt, Scott H Randell, Carl W White, Aftab Ahmad

    Published 2011-01-01
    Get full text
    Article
  3. 3
    Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation.

    Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mut... by Kerstin Pohl, David P Nichols, Jennifer L Taylor-Cousar, Milene T Saavedra, Matthew J Strand, Jerry A Nick, Preston E Bratcher

    Published 2018-01-01
    Get full text
    Article
  4. 4
    Mycobacterium abscessus morphotype comparison in a murine model.

    Mycobacterium abscessus morphotype comparison in a murine model. by Lindsay J Caverly, Silvia M Caceres, Cori Fratelli, Carrie Happoldt, Kelley M Kidwell, Kenneth C Malcolm, Jerry A Nick, David P Nichols

    Published 2015-01-01
    Get full text
    Article
  5. 5
    Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis

    Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis by Kadambari Vijaykumar, Hui Min Leung, Amilcar Barrios, Justin Wade, Heather Y. Hathorne, David P. Nichols, Guillermo J. Tearney, Steven M. Rowe, George M. Solomon

    Published 2024-04-01
    Get full text
    Article
  6. 6
    Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR.

    Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR. by Robert L Young, Kenneth C Malcolm, Jennifer E Kret, Silvia M Caceres, Katie R Poch, David P Nichols, Jennifer L Taylor-Cousar, Milene T Saavedra, Scott H Randell, Michael L Vasil, Jane L Burns, Samuel M Moskowitz, Jerry A Nick

    Published 2011-01-01
    Get full text
    Article
  7. 7
    Blood mRNA biomarkers distinguish variable systemic and sputum inflammation at treatment initiation of inhaled antibiotics in cystic fibrosis: A prospective non-randomized trial.

    Blood mRNA biomarkers distinguish variable systemic and sputum inflammation at treatment initiation of inhaled antibiotics in cystic fibrosis: A prospective non-randomized trial. by Silvia M Caceres, Linda A Sanders, Noel M Rysavy, Katie R Poch, Caroline R Jones, Kyle Pickard, Tasha E Fingerlin, Roland A Marcus, Kenneth C Malcolm, Jennifer L Taylor-Cousar, David P Nichols, Jerry A Nick, Matthew Strand, Milene T Saavedra

    Published 2022-01-01
    Get full text
    Article
  8. 8
    Extremes of Interferon-Stimulated Gene Expression Associate with Worse Outcomes in the Acute Respiratory Distress Syndrome.

    Extremes of Interferon-Stimulated Gene Expression Associate with Worse Outcomes in the Acute Respiratory Distress Syndrome. by Jerry A Nick, Silvia M Caceres, Jennifer E Kret, Katie R Poch, Matthew Strand, Anna V Faino, David P Nichols, Milene T Saavedra, Jennifer L Taylor-Cousar, Mark W Geraci, Ellen L Burnham, Michael B Fessler, Benjamin T Suratt, Edward Abraham, Marc Moss, Kenneth C Malcolm

    Published 2016-01-01
    Get full text
    Article
  9. 9
    Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist

    Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist by David P. Nichols, Sarah J. Morgan, Michelle Skalland, Anh T. Vo, Jill M. Van Dalfsen, Sachinkumar B.P. Singh, Wendy Ni, Lucas R. Hoffman, Kailee McGeer, Sonya L. Heltshe, John P. Clancy, Steven M. Rowe, Peter Jorth, Pradeep K. Singh, the PROMISE-Micro Study Group

    Published 2023-05-01
    Get full text
    Article

Search Tools: